benefit 1
highdose 1
daunorubicin 1
aml 1
induction 1
extends 1
across 1
cytogenetic 1
molecular 1
groups 1
phase 2
ii 2
randomized 1
trial 2
comparing 1
standard 1
low 1
dose 1
rituximab 1
combined 1
alemtuzumab 1
initial 1
treatment 1
progressive 1
chronic 1
lymphocytic 1
leukemia 3
older 1
patients 2
ecogacrin 1
cancer 1
research 1
group 2
e 2
significant 1
improvements 1
practice 1
patterns 1
adult 1
related 1
donor 4
care 1
transplantation 4
centers 2
hematopoietic 1
cell 1
outcomes 2
monosomal 1
karyotype 1
myeloid 2
malignancies 1
analysis 1
effect 2
race 1
socioeconomic 1
status 1
center 1
size 1
unrelated 1
national 1
marrow 2
program 1
toxicities 1
more 1
common 1
lowvolume 1
bone 1
collection 1
immunosuppressive 1
therapy 2
lgl 1
prospective 1
multicenter 1
study 1
eastern 1
cooperative 1
oncology 1
postremission 1
before 1
reducedintensity 1
conditioning 1
allogeneic 2
acute 1
complete 2
remission 2
ph 1
similar 1
survival 1
reduced 1
intensity 1
myeloablative 1
impact 1
tyrosine 1
kinase 1
inhibitor 1
minimal 1
residual 1
disease 1
